What is the mechanism of action of carbetocin, and what is the optimal timing, route (intravenous versus intramuscular), and dosage for its administration to prevent postpartum uterine atony?

Carbetocin: Mechanism, Timing, and Administration

Carbetocin is a long-acting synthetic oxytocin analogue that should be administered as a single 100 μg intravenous bolus immediately after delivery of the infant (or anterior shoulder in vaginal delivery) to prevent uterine atony and postpartum hemorrhage.

Mechanism of Action

Carbetocin functions as an oxytocin receptor agonist, binding to oxytocin receptors on uterine smooth muscle to induce sustained uterine contractions. The key pharmacologic advantage is its prolonged half-life of 4-10 times longer than oxytocin 1, providing sustained uterotonic activity comparable to ergot alkaloids but with the superior safety profile of oxytocin 1. This extended duration of action eliminates the need for continuous infusion, unlike oxytocin which requires maintenance dosing.

Optimal Timing

Administer carbetocin immediately after delivery of the infant:

• Cesarean delivery: Give at the time of infant delivery
• Vaginal delivery: Give at delivery of the anterior shoulder of the neonate 2

This timing aligns with active management of the third stage of labor to prevent postpartum hemorrhage before uterine atony develops.

Route of Administration: IV Preferred

Intravenous administration is the optimal route based on the evidence:

• All major trials demonstrating efficacy used 100 μg IV bolus 3, 4
• IV route provides more predictable pharmacokinetics and faster onset
• While intramuscular administration is possible 1, the evidence base predominantly supports IV dosing for both cesarean and vaginal deliveries

Dosing Strategy

Standard Dose

100 μg IV bolus is the established effective dose across multiple high-quality studies 4, 5, 6, 7

Dose Considerations by Clinical Context

For low-risk elective cesarean delivery:

• Recent 2026 data suggests doses as low as 20-100 μg may be similarly effective 8
• However, a 2019 non-inferiority trial failed to confirm that 20 μg was non-inferior to 100 μg 2
• Recommendation: Use 100 μg until more definitive evidence supports lower dosing

For preeclampsia:

• Higher doses are required: ED90 of 96 μg (vs 68 μg in non-preeclamptic patients) 9
• Dose requirement is approximately 1.5 times greater in preeclamptic patients 9
• Use 100 μg or consider up to 120 μg in severe preeclampsia

For high-risk patients or intrapartum cesarean:

• Use 100 μg IV bolus as standard
• These patients have higher uterotonic requirements similar to oxytocin dosing patterns 3

Clinical Advantages Over Oxytocin

The 2026 ERAS guidelines note that carbetocin is "probably the most effective agent" based on 2021 network meta-analysis 3. Key advantages include:

• Single bolus dosing vs. oxytocin's requirement for initial bolus plus maintenance infusion 1, 4
• Reduced need for additional uterotonics: OR 0.67 compared to oxytocin 6
• Less blood loss: Mean difference of -28.13 mL in first 24 hours 6
• Smaller hemoglobin drop: -0.39 g/dL less decrease 6
• Faster placental separation and shorter third stage 5

Important Caveats

Availability: Carbetocin is not available in the United States 3. Where unavailable, follow oxytocin dosing strategies per ERAS guidelines.

Contraindications:

• Preeclampsia remains a contraindication in the EU, though emerging evidence suggests efficacy 1, 9
• Standard oxytocin contraindications apply

Side Effect Profile: Similar to oxytocin (nausea, tachycardia, hypotension) but significantly better than syntometrine, with lower rates of nausea (OR 0.24), vomiting (OR 0.21), and hypertension 4

Administration Technique: Give as slow IV bolus (not rapid push) to minimize hemodynamic effects, similar to oxytocin administration principles 3

Comparison to Syntometrine

When compared to syntometrine for vaginal delivery, carbetocin demonstrates:

• 35 mL less blood loss (though not statistically significant, p=0.09) 6
• Significantly fewer adverse effects, particularly nausea, vomiting, and hypertension 4
• Similar efficacy in preventing PPH 4, 6

Clinical Bottom Line: Where available, carbetocin 100 μg IV bolus at delivery represents the most effective single-agent uterotonic for PPH prevention, offering superior efficacy to oxytocin with single-dose convenience and better tolerability than syntometrine 3, 4, 5, 6, 7.